Azithromycin: Antibiotic and not only...
https://doi.org/10.21518/ms2024-375
Abstract
Antibacterial therapy is an essential component of treatment for bacterial respiratory infections. The last decade has seen an increase in resistance of respiratory pathogens to different classes of antibiotics. The purpose of this review was to analyze publications on azithromycin, a macrolide with both antibacterial and non-antibacterial properties. Studies conducted worldwide indicate heterogeneity in both the frequency of azithromycin use and resistance to it, but in general, there is an increase in the values of its minimum inhibitory concentration against pathogens for which the use of macrolides is indicated. The COVID-19 pandemic has led to an expansion of clinical experience with the use of this azalide, demonstrating sufficient safety of the drug. However, recent large retrospective studies have shown the inappropriateness of its etiotropic use in this viral infection, limiting it only to proven cases of bacterial pneumonia caused by pathogens sensitive to macrolides. One of the ways to optimize the use of azithromycin is its combined use with other drugs that provide synergy in clinical effectiveness. An important property of azithromycin, ensuring its clinical effectiveness, is its ability to affect inflammatory processes in the respiratory tract, the state of the respiratory epithelium. The anti-inflammatory properties of azithromycin are used in various fields of medicine, including traumatology, gynecology and dentistry. The clinical effectiveness of antibiotics is determined by their rational use, patient compliance and convenience of the dosage form. In this regard, work is underway to create forms convenient for oral administration, to overcome the bitter taste. In this direction, certain successes have been achieved by domestic developers in the introduction of a dispersible form of azithromycin.
About the Authors
A. A. Vizel
Kazan State Medical University
Russian Federation
Russian Federation
Alexander A. Vizel - Dr. Sci. (Med.), Professor, Head Department, Kazan State Medical University.
49, Butlerov St., Kazan, 420012
Author ID: 195447
I. Yu. Vizel
Kazan State Medical University
Russian Federation
Russian Federation
Irina Yu. Vizel - Dr. Sci. (Med.), Professor of RAE, Associate Professor of the Department of Phthisiopulmonology, Kazan State Medical University.
49, Butlerov St., Kazan, 420012
Author ID: 246946
A. Sh. Zalilova
Kazan State Medical University
Russian Federation
Russian Federation
Alina Sh. Zalilova - Clinical Resident of the Department of Phthisiopulmonology, Kazan State Medical University.
49, Butlerov St., Kazan, 420012
References
1. Greenwood D. Antimicrobial Drugs. Chronicle of a twentieth century medical triumph. Oxford: Oxford University Press; 2008. 464 p.
2. Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet. 1993;25(5):370-374. https://doi.org/10.2165/00003088-199325050-00003.
3. Bakheit AH, Al-Hadiya BM, Abd-Elgalil AA. Azithromycin. Profiles Drug Subst Excip Relat Methodol. 2014;39:1-40. https://doi.org/10.1016/B978-0-12-800173-8.00001-5.
4. Heidary M, Ebrahimi Samangani A, Kargari A, Kiani Nejad A, Yashmi I, Motahar M et al. Mechanism of action, resistance, synergism, and clinical implications of azithromycin. J Clin Lab Anal. 2022;36(6):e24427. https://doi.org/10.1002/jcla.24427.
5. Kharaeva ZF, Elgarova DA, Kablakhova NO, Blieva LZ, Barokova EB, Kambachokova ZA, Elmurzaeva DA. Antibiotic sensitivity and antilysozyme activity of Staphylococcus aureus strains isolated from the blood of patients with sepsis. Antibiotics and Chemotherapy. 2020;65(11-12):11-15. (In Russ.) https://doi.org/10.37489/0235-2990-2020-65-11-12-11-15.
6. Minetti C, Barton R, Farley C, Spiller OB, Rodrigues R, Gongalves P. Antimicrobial susceptibility testing reveals reduced susceptibility to azithromycin and other antibiotics in Legionella pneumophila serogroup 1 isolates from Portugal. Eur J Clin Microbiol Infect Dis. 2024;43(7):1297-1308. https://doi.org/10.1007/s10096-024-04789-9.
7. Jiang Y, Dou H, Xu B, Xu B, Zhou W, Wang H et al. Macrolide resistance of Mycoplasma pneumoniae in several regions of China from 2013 to 2019. Epidemiol Infect. 2024;152:e75. https://doi.org/10.1017/S0950268824000323.
8. Yang J. Mechanism of azithromycin in airway diseases. J Int Med Res. 2020;48(6):300060520932104. https://doi.org/10.1177/0300060520932104.
9. Iskalieva AR, Eresko SO, Airapetov MI. Prospects for the use of azithromycin in neuroinflammation. Forcipe. 2021;4(S1):888-889. (In Russ.) Available at: https://ojs3.gpmu.org/index.php/forcipe/article/view/3626.
10. Xu S, Xing J, Zheng L, Su H, Zou Y, Niu Y, Di H. Azithromycin regulates Mettl3-mediated NF-KB pathway to enhance M2 polarization of RAW264.7 macrophages and attenuate LPS-triggered cytotoxicity of MLE-12 alveolar cells. Int Immunopharmacol. 2024;137:112426. https://doi.org/10.1016/j.intimp.2024.112426.
11. Taguchi K, Chuang VTG, Ogino H, Hara R, Iketani O, Enoki Y et al. Direct comparison of anti-inflammatory effects of 14-, 15-, and 16-membered macrolide antibiotics in experimental inflammation model induced by carrageenan in rats. Pharmazie. 2024;79(3):64-66. https://doi.org/10.1691/ph.2024.3667.
12. Kadushkin AG, Tahanovich AD, Movchan LV, Kolesnikova TS, Khadasouskaya EV, Shman TV. The Effect of Glucocorticoids in Combination with Azithromycin or Theophylline on Cytokine Production by NK and NKT-Like Blood Cells of Patients with Chronic Obstructive Pulmonary Disease. Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry. 2021;15:337-344. https://doi.org/10.1134/S1990750821040053.
13. Janjua S, Mathioudakis AG, Fortescue R, Walker RA, Sharif S, Threapleton CJ, Dias S. Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis. Cochrane Database Syst Rev. 2021;1(1):CD013198. https://doi.org/10.1002/14651858.CD013198.pub2.
14. Skryabina AA, Nikiforov VV, Shakhmardanov MZ, Zastrozhin MS, Sychev DA. Non-antimicrobial effects of macrolides: literature review. Immunopathology, Allergology, Infectology. 2021;(4):20-27. (In Russ.) https://doi.org/10.14427/jipai.2021.4.20.
15. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial.Lancet. 2О17;39О(10095):659-668. https://doi.org/10.1016/S0140-6736(17)31281-3.
16. Douglas LC, Choi J, Esteban-Cruciani N. Azithromycin treatment in children hospitalized with asthma: a retrospective cohort study. J Asthma. 2020;57(5):525-531. https://doi.org/10.1080/02770903.2019.1590590.
17. Khamitov RF, Palmova LYu, Novozhenov VG. Significance of antibacterial therapy of Chlamydophila pneumoniae infection in patients with bronchial asthma. TerapevticheskiiArkhiv. 2004;79(10):91-93. (In Russ.) Available at: https://ter-arkhiv.ru/0040-3660/article/view/29953.
18. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur RespirJ. 2009;33(1):153-159. https//doi.org/10.1183/09031936.00054108.
19. Che SY, He H, Deng Y, Liu EM. Clinical effect of azithromycin adjuvant therapy in children with bronchiolitis: a systematic review and Meta analysis. Zhongguo Dang Dai Er Ke Za Zhi. 2019;21(8):812-819. (In Chinese) https://doi.org/10.7499/j.issn.1008-8830.2019.08.014.
20. Mamonova IA, Babushkina IV, Ulyanov VYu, Shpinyak SP. Biofilm formation in Pseudomonas aeruginosa strains - the pathogens of implant-associated infection in larger joints in the presence of azithromycin. Problems in Medical Mycology. 2021;23(2):109. (In Russ.) Available at: https://mycology.szgmu.ru/images/files/2021/2_2021.pdf.
21. Southern KW, Solis-Moya A, Kurz D, Smith S. Macrolide antibiotics (including azithromycin) for cystic fibrosis. Cochrane Database Syst Rev. 2024;2(2):CD002203. https://doi.org/10.1002/14651858.CD002203.pub5.
22. Snigireva OA, Persov RA, Trutneva MS. The revival of azithromycin in the era of COVID-2019.Shkola Nauki. 2020;(11):37-38. (In Russ.) Available at: https://www.elibrary.ru/gbwsdg.
23. Vizel AA, Abdulganieva DI, Bayalieva AD, Vanyushin AA, Salakhova IN, Vafina AR et al. The analysis of management of patients with COVID-19: experience of the first 5 months. Prakticheskaya Pulmonologiya. 2020;(3):61-72. (In Russ.) Available at: http://www.atmosphere-ph.ru/modules/Magazines/articles//pulmo/pp_3_2020_61.pdf.
24. Khoshnood S, Shirani M, Dalir A, Moradi M, Haddadi MH, Sadeghifard N et al. Antiviral effects of azithromycin: A narrative review. Biomed Pharmacother. 2022;147:112682. https://doi.org/10.1016/j.biopha.2022.112682.
25. Skryabina AA, Nikiforov VV, Shakhmardanov MZ, Zastrozhin MS, Skryabin VYu, Sychev DA. Adverse drug reactions of macrolide therapy: analysis of spontaneous reports according to the Pharmacovigilance system. Clinical Microbiology and Antimicrobial Chemotherapy. 2023;25(1):34-40. (In Russ.) https://doi.org/10.36488/cmac.2023.1.34-40.
26. Gagliotti C, Banchelli F, Buttazzi R, Ricchizzi E, Canziani LM, Rolli M et al. Use of Azithromycin Attributable to Acute SARS-CoV-2 Infection. Pharmacoepidemiol Drug Saf. 2024;33(7):e5857. https://doi.org/10.1002/pds.5857.
27. Lee N, Wong CK, Chan MCW, Yeung ESL, Tam WWS, Tsang OTY et al. Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial. Antiviral Res. 2017;144:48-56. https://doi.org/10.1016/j.antiviral.2017.05.008.
28. Madioko Makanzu B, Makulo JR, Ndona Mandina M, Wumba DR, Mashi Longokolo M, Situakibanza H et al. Hydroxychloroquine-azithromycin, doubase C, and QTc prolongation in congolese patients with COVID-19: Myth or reality? World J Virol. 2024;13(2):90668. https://doi.org/10.5501/wjv.v13.i2.90668.
29. Mutalimova LR, Khanova RSh. The role of azithromycin in the treatment of upper respiratory tract infections. Medicus. 2024;(3):41-45. (In Russ.) Available at: http://scimedicus.ru/f/medicus_no_3_57_march.pdf.
30. Uryasev OM, Shakhanov AV, Korshunova LV. Effectiveness of antimicrobial therapy for community-acquired pneumonia in real clinical practice. Bulletin of Siberian Medicine. 2021;20(4):79-85. (In Russ.) https://doi.org/10.20538/1682-0363-2021-4-79-85.
31. Alexandrova TV, Muslimova OV, Zhuravleva MV, Alexandrov AA, Gorodetskaya GI, Demchenkova EYu et al. Evaluation of the efficacy and safety of initial empirical antibiotic therapy for community-acquired pneumonia in middle-aged people. Safety and Risk of Pharmacotherapy. 2022;10(2):118-127. (In Russ.) https://doi.org/10.30895/2312-7821-2022-10-2-118-127.
32. Taube AA, Demidova OA, Alexandrova TV, Stepanov EA, Zhuravleva MV, Alyautdin RN. Analysis of antibiotic prescriptions in patients with community-acquired pneumonia in clinical practice. Clinical Microbiology and Antimicrobial Chemotherapy. 2022;24(4):388-394. (In Russ.) https://doi.org/10.36488/cmac.2022.4.388-394.
33. Taube AA, Makarchenkov AA Zhuravleva MV. Clinical and economic analysis of antimicrobial therapy strategies for community-acquired pneumonia in real clinical practice. Pharmacoeconomics: Theory and Practice. 2023;11(3):14-23. (In Russ.) https://doi.org/10.30809/phe.3.2023.2.
34. Ding H, Mang NS, Loomis J, Ortwine JK, Wei W, O'Connell EJ et al. Incidence of drug-resistant pathogens in community-acquired pneumonia at a safety net hospital. Microbiol Spectr. 2024;12(8):e0079224. https://doi.org/10.1128/spectrum.00792-24.
35. Sykes DL, Mason P, Rahunathan N, Hart SP, Morice AH, Crooks MG. The Effect of Long-Term Azithromycin on Objective and Subjective Cough in Chronic Respiratory Disease: A Systematic Review and Meta-analysis of Randomised Controlled Trials and Noncomparative Studies. Lung. 2024;202:569-579. https://doi.org/10.1007/s00408-024-00729-8.
36. Sukhanov DS, Maryushkina VS, Azovtsev DYu. Modern features of acute bronchitis therapy. The effect and advantages of the dispersible form of antibacterial drugs. Lechaschi Vrach. 2022;(3):70-75. (In Russ.) Available at: https://www.lvrach.ru/2022/03/15438251.
37. Zaker H, Taymouri S, Mostafavi A. Formulation and physicochemical char-acterization of azithromycin-loaded cubosomes. Res Pharm Sci. 2022;18(1):49-58. https://doi.org/10.4103/1735-5362.363595.
38. Dung PT, Trinh TD, Nguyen QH, Nguyen HM, Nguyen NC, Tran NB et al. Development of taste-masking microcapsules containing azithromycin by fluid bed coating for powder for suspension and in vivo evaluation. J Microencapsul. 2023;40(5):345-356. https://doi.org/10.1080/02652048.2023.2209639.
39. Huynh DTM, Hai HT, Hau NM, Lan HK, Vinh TP, Tran V, Pham DT. Preparations and characterizations of effervescent granules containing azithromycin solid dispersion for children and elder: Solubility enhancement, taste-masking, and digestive acidic protection. Heliyon. 2023;9(6):e16592. https://doi.org/10.1016/j.heliyon.2023.e16592.
40. Tyutyunnik VL, Mikhailova OI, Kan NE, Mirzabekova DD. Modern concepts of therapy of urogenital chlamydia during pregnancy. Akusherstvo i Ginekologiya (Russian Federation). 2024;(4):148-155. (In Russ.) https://doi.org/10.18565/aig.2024.64.
Review
For citations:
Vizel AA, Vizel IY, Zalilova AS. Azithromycin: Antibiotic and not only... Meditsinskiy sovet = Medical Council. 2024;(20):168-175. (In Russ.) https://doi.org/10.21518/ms2024-375
Views:
336
Email this article 